Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc. is a biotechnology company that develops a platform for cell engineering. Its business is organized into two segments: Cell Engineering and Biosecurity. The Cell Engineering segment offers R&D solutions and tools such as functional genomics, antibody developability, small molecule developability, artificial intelligence models, and reconfigurable automation cart systems. These are used to research, develop, and commercialize engineered organisms and derived products. The Biosecurity segment provides biomonitoring and bioinformatics support through Canopy, which generates genomic data from strategically positioned nodes, and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. The company also offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization.

Ginkgo Bioworks Holdings, Inc. is listed on the New York Stock Exchange (NYSE) under the ticker symbol DNA. The company's financials are reported in US Dollars (USD), as it is based in the United States. Being listed on a major US exchange provides liquidity and access to a broad investor base.

Ginkgo Bioworks operates in the Healthcare sector, specifically within the Biotechnology industry. Biotechnology involves using living organisms or their components to develop products and technologies for various applications, including healthcare, agriculture, and industrial processes. As a biotechnology company, Ginkgo focuses on cell engineering to create custom organisms for clients across multiple industries.

Ginkgo Bioworks is headquartered in Boston, Massachusetts, United States. Founded in 2008, the company serves a diverse range of industries including pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense. Its platform enables clients to engineer cells for applications such as drug development, crop improvement, and biosecurity monitoring.

Ginkgo Bioworks generates revenue through its Cell Engineering and Biosecurity segments. In the Cell Engineering segment, it offers R&D services and tools to help clients develop engineered organisms and derived products. This includes functional genomics, AI models, and automation systems. The Biosecurity segment provides biomonitoring services via Canopy, which collects genomic data from nodes, and Horizon, a digital platform for detecting biothreats. The company also offers genetic medicine R&D, protein engineering, and crop optimization services, serving clients across pharmaceuticals, agriculture, and government sectors.